Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review

• DOI: 10.3389/fonc.2023.976415
• Publication Date: 2023-03-16T17:02:57Z
• Authors: Zichang Liu; Maosheng Yu; Feng Zhao; Chenfang Zhu
• Keywords: Fulminant

Primary squamous cell carcinoma of the thyroid (PSCCT) is a rare malignant tumor. The incidence rate PSCCT less than 1%. However, diagnosis and treatment are limited. Surgical resection considered to be one few effective intervention methods. In this article, we reported case taking tyrosine kinase inhibitors (TKIs) combined with immune checkpoint (ICIs) for PSCCT.An 80-year-old male was admitted our hospital dyspnea, cough, wheezing, hoarseness giant mass. He underwent bronchoscopy tracheal stent implantation alleviate respiratory obstruction. Then he accepted right partial lymph node biopsy. Postoperative pathology revealed carcinoma. Subsequently, an endoscopy exclude upper gastrointestinal Finally, diagnosed PSCCT. patient tentatively treated combination Anlotinib Sintilimab. After two courses, tumor volume significantly reduced in MRI images shrank further after five courses treatment. Unfortunately, died fulminant liver failure autoimmune disease 5-month-treatment.TKIs ICIs may novel way treatment, but immune-related complications, especially damage, should cared.